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ABSTRACT
Introduction: Metformin is an established first-
line treatment for patients with type 2 diabetes
mellitus (T2DM), but treatment intensification
with other oral antidiabetes drugs (OADs) is
usually required over time. Effectiveness of
diabetes control with vildagliptin and
vildagliptin/metformin was a 1-year, large
observational study of 45,868 patients with
T2DM across 27 countries which assessed
effectiveness and safety of vildagliptin as add-
on therapy to other OADs versus other
comparator OAD combinations. Here, we
present the data from Germany.
Methods: Patients inadequately controlled
with monotherapy were eligible only after the
add-on treatment was finalized. Patients were
assigned to either vildagliptin or comparator
OADs [sulfonylureas, thiazolidinediones,
glinides, a-glucosidase inhibitors or
metformin, excluding dipeptidyl peptidase 4
(DPP-4) inhibitors or glucagon-like peptide-1
mimetic/analogues]. The primary efficacy
endpoint was the proportion of patients
achieving a glycosylated hemoglobin (HbA1c)
reduction of [0.3% without peripheral edema,
hypoglycemia, discontinuation due to a
gastrointestinal event or weight gain C5%.
One secondary efficacy endpoint was the
proportion of patients achieving HbA1c \7%
without hypoglycemia and weight gain.
Change in HbA1c from baseline to study
endpoint and safety were assessed.
Results: Of 8,887 patients enrolled in Germany,
6,679 received vildagliptin and 1,695 received
other OADs. The mean ± SD baseline age, HbA1c,
and T2DM duration were 62.8 ± 11.0 years,
7.7 ± 1.2%, and 5.8 ± 4.9 years, respectively.
The proportion of patients achieving the
primary (34.5% vs. 30.5%, p\0.01) and
secondary (25.4% vs. 21.7%, p = 0.01)
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endpoints was higher with vildagliptin than
comparator OADs. Vildagliptin showed a
numerically greater reduction in HbA1c (0.7%)
from baseline vs. comparator OADs (0.6%). The
overall incidence of adverse events was similar.
Conclusion: In real life, treatment with
vildagliptin is associated with a higher
proportion of patients reaching target HbA1c
without hypoglycemia and weight gain
compared with other OADs in Germany.
Keywords: Diabetes; Dipeptidyl peptidase 4
inhibitors; Endocrinology; Glycosylated
hemoglobin; Observational study; Oral
antidiabetes agents; Real life; Type 2 diabetes
mellitus; Vildagliptin
INTRODUCTION
The prevalence of diabetes in Germany has been
predicted to increase in the next two decades
with about 3.9 million people aged 55–74 years
affected by type 2 diabetes mellitus (T2DM) in
2030 [1]. This would result in a 79% increase in
annual costs between 2010 and 2040 [2].
T2DM is a progressive disease and its long-
term management warrants intensification of
treatment and a patient-centric approach based
on benefits and risks for the individual
concerned [3]. Metformin is often
recommended as the first-line treatment for
patients with T2DM, but addition of other
antihyperglycemic agents is usually required
over time [3]. Sulfonylureas (SUs) are
commonly used in patients when metformin
monotherapy fails to achieve glycemic control.
However, use of SUs is associated with adverse
effects such as hypoglycemia and weight gain
[4].
Vildagliptin is a potent and selective
dipeptidyl peptidase-4 (DPP-4) inhibitor that
improves glycemic control by increasing a- and
b-cell responsiveness to glucose. Vildagliptin as
monotherapy or in combination has been
shown to be weight neutral with no additional
risk of hypoglycemia [5–7]. The weight
neutrality and low risk of hypoglycemia with
DPP-4 inhibitors has also been confirmed from a
recent meta-analysis that assessed the safety and
efficacy of all available second-line
antihyperglycemic therapies in patients with
T2DM inadequately controlled by metformin
monotherapy [8].
Pragmatic real-life observational studies are
designed to provide a closer look into routine
clinical practice and thus can serve as additional
evidence to randomized clinical trials, which
are conducted in a predefined patient
population under controlled conditions [9–11].
Effectiveness of Diabetes control with
vildaGliptin and vildagliptin/mEtformin
(EDGE) was a prospective, 1-year, real-life
observational study conducted across 27
countries that assessed the effectiveness and
tolerability of vildagliptin added to
monotherapy with an oral antidiabetes drug
(OAD) (vildagliptin cohort), compared with
other OAD combinations (comparator OAD
cohort) [12]. Here, we present the results of a
post hoc analysis from the EDGE study in
patients with T2DM in Germany.
METHODS
Study Design and Patients
Of the 45,868 patients enrolled in the EDGE
study, 8,887 patients were enrolled in Germany
(Fig. 1a). Patients with T2DM, aged [18 years
inadequately controlled on OAD monotherapy
with an SU, metformin, thiozolidinediones
(TZD), glinide or a-glucosidase inhibitor were
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eligible. Patients receiving DPP-4 inhibitors
other than vildagliptin, incretin mimetics/
analogues or insulin, requiring three or more
OADs, or having a history of hypersensitivity to
study drugs were excluded.
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors. All
participants provided a written or oral informed
consent before participation in the study.
Physicians chose antidiabetic treatment for
their patients at their own discretion. To avoid
bias for a particular choice of treatment by the
physician, enrolment of patients was agreed
only after the treatment decision was made. The
term ‘index therapy’ was used to represent the
combination treatment initiated at enrolment.
Fig. 1 a Study design of German subgroup analysis.
*Vildagliptin cohort: T2DM patients newly initiating
vildagliptin as add-on dual therapy or newly initiating
vildagliptin/metformin (ﬁxed-dose) from non-vildagliptin
monotherapy. **Comparator OAD cohort: T2DM patients
newly initiating therapy with OADs other than vildagliptin
(deﬁned as SU, metformin, TZDs, metiglinides, a-glucosi-
dase inhibitors as add-on dual therapy) except as add-on to
vildagliptin, other DPP-4 inhibitors, or GLP-1 mimetics/
analogues. AEs Adverse events, BL baseline, HbA1c
glycosylated hemoglobin, OADs oral antidiabetes drugs,
SAEs severe adverse events, T2DM type 2 diabetes mellitus,
TZDs thiozolidinediones. b Percentage of patients taking
index medication (ITT population). AGI a-glucosidase
inhibitor, ITT intention-to-treat, OAD antidiabetes drugs,
SU sulphonylurea, TZD thiazolidinedione, vilda vildaglip-
tin. *Initial (prior) monotherapy is given ﬁrst within a
treatment. For 12 patients in the vildagliptin cohort and 4
in the comparator cohort, it was not possible to identify the
index medication
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For any index therapy, a fixed-dose
combination, if available, was allowed. Details
of the subjects and study design are reported
elsewhere [12].
Efficacy and Safety Assessments
The primary efficacy endpoint was the
proportion of patients having a treatment
response of HbA1c reduction [0.3% from
baseline to 12-month endpoint without
peripheral edema, hypoglycemic event,
discontinuation due to a gastrointestinal
event, or weight gain C5%. One of the secondary
efficacy endpoints was the proportion of patients
achieving HbA1c \7.0% without hypoglycemic
events and weight gain C3% in patients with
baseline HbA1c C7% at 12-month endpoint
(responder rate). Change in HbA1c from baseline
to 12-month endpoint (analysis not pre-specified
in the protocol) and the number of hypoglycemic
events were also evaluated in this post hoc
analysis. Hypoglycemia was defined as presence
of symptoms suggestive of hypoglycemia
including mild and severe events that
resolved promptly on administration of oral
carbohydrate. Safety assessments including body
weight, adverse events (AEs) and serious AEs
(SAEs) were recorded.
Statistical Analysis
Descriptive statistics were used for these post
hoc analyses. The per protocol (PP) population
was a subset of the intention-to-treat (ITT)
population without protocol deviation and
was used for the analysis of efficacy endpoints.
Data were censored if patients changed index
therapy. A binary logistic regression model was
used to calculate odds ratios (ORs) with 95%
confidence intervals (CIs) for the probability of
success in achieving the primary and secondary
endpoints with the vildagliptin cohort versus
the comparator OAD cohort. Patients whose
outcomes could not be categorized as a success
or failure (e.g., due to missing HbA1c or body
weight data at the 12-month endpoint) were
considered non-evaluable. These non-evaluable
patient data were considered failures in the
calculation of the OR for success. The OR
expresses odds in favor of success with
vildagliptin combination relative to odds in
favor of success with comparator OADs. Only
unadjusted ORs were reported for the primary
and secondary endpoints in this post hoc
analysis. The change in HbA1c in both groups
was not pre-specified in the protocol, HbA1c
drop was adjusted with HbA1c baseline by using
the analysis of co-variance (ANCOVA) model.
RESULTS
Patient Demographics and Baseline
Characteristics
Of the 8,887 patients enrolled from Germany in
the EDGE study, 513 patients (377 in the
vildagliptin cohort and 124 in the comparator
OAD cohort plus 12 without cohort assigned)
were excluded due to inadequate source
documentation or problems with quality or
accuracy of data entry. The remaining ITT
population, used for baseline demographics
and safety analyses, comprised patients
receiving dual therapy with newly prescribed
vildagliptin (n = 6,679) or a non-vildagliptin
OAD added to prior monotherapy (n = 1,695)
(Table 1). The PP population comprised 6,501
patients in the vildagliptin cohort, and 1,686
patients in the comparator OAD cohort.
The demographic and baseline
characteristics of patients in the ITT
population are summarized in Table 2. After
initiating combination therapy 6,439 patients
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(96.6% of the vildagliptin cohort) received
metformin–vildagliptin and 971 patients
(57.4% of the comparator OAD cohort)
received metformin–SUs (Fig. 1b).
Efficacy and Safety Assessments
The primary endpoint was reached in 34.5%
and 30.5% of patients in the vildagliptin and
comparator OAD cohorts, respectively, with
unadjusted OR 1.2 (95% CI 1.07, 1.35;
p\0.01) significantly in favor of vildagliptin.
In the vildagliptin cohort, a higher proportion
of patients reached the responder rate of HbA1c
\7.0% without hypoglycemia and weight gain
when compared with comparator OAD cohort
(vildagliptin, 25.4%; comparator OADs,
21.7%), with an unadjusted OR of 1.23 (95%
Table 1 Patient populations and ﬂow
Enrolleda 8,887





Assigned to 7,056 1,819
No adequate source documentation at site; lack of quality
and accuracy of data entry
377 124
ITTb 6,679 1,695
Patients completed, n (%) 4,934 (73.9) 1,386 (81.8)
Patients discontinued, n (%) 1,745 (26.1) 309 (18.2)
Lost to follow-up 821 (47.0) 129 (41.7)
Administrative 664 (38.1) 147 (47.6)
Unsatisfactory therapeutic effect 84 (4.8) 6 (1.9)
Subject withdrew consent 49 (2.8) 12 (3.9)
Patients with C1 protocol deviation 48 (2.8) 3 (1.0)
Adverse events 32 (1.8) 2 (0.6)
Abnormal laboratory values 16 (0.9) 2 (0.6)
Subject’s condition no longer requires study drug 15 (0.9) 0
Death 13 (0.7) 8 (2.6)
Missing 2 0
Abnormal test procedure results 1 (0.1) 0
Per protocolc 6,501 1,686
OAD oral antidiabetes drugs
a The enrolled population includes all patients who gave documented informed consent
b The intent-to-treat (ITT) population is a subset of the enrolled population and includes all patients who were assigned to
new treatment at study start
c The per protocol (PP) population is a subset of the ITT population, who completed the study without any major protocol
deviation. It was used for the analyses of effectiveness endpoints
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CI 1.05, 1.43; p = 0.01) in favor of vildagliptin
(Fig. 2).
After 1-year of treatment, HbA1c decreased in
both cohorts from baseline to endpoint (-0.7%
in the vildagliptin cohort vs. -0.6% in the
comparator OAD cohort), with a mean
treatment difference of -0.11% (95% CI -0.17,
-0.06) in favor of vildagliptin (Fig. 3).
Overall, 342 patients (5.1%) in the
vildagliptin cohort and 86 patients (5.1%) in
the comparator OAD cohort reported AEs. The
overall occurrence of SAEs was low in both the
cohorts: 62 patients reported SAEs in the
vildagliptin cohort (0.9%) and 16 in the
comparator cohort (0.9%). However, none of
the SAEs were suspected to be drug-related. A
total of eight patients (0.1%) reported
hypoglycemia in the vildagliptin cohort vs.
four patients in the comparator OAD cohort
(0.2%). The mean decrease in body weight from







Age (years) 62.4 ± 11.1 64.5 ± 10.6 62.8 ± 11.0
Gender, n (%)
Male 3,641 (54.5) 888 (52.4) 4,529 (54)
Female 3,038 (45.5) 807 (47.6) 3,845 (46)
BMI (kg/m2) 30.9 ± 5.5 30.0 ± 5.1 30.7 ± 5.4
HbA1c (%) 7.8 ± 1.2 7.6 ± 1.2 7.7 ± 1.2
Duration of T2DM
(years)
5.7 ± 4.9 6.2 ± 5.0 5.8 ± 4.9
Data are mean ± SD unless speciﬁed otherwise
BMI body mass index, ITT intention-to-treat, SD standard deviation, T2DM type 2 diabetes mellitus, HbA1c glycosylated
hemoglobin, OAD oral antidiabetes drugs
Fig. 2 Percentage of patients achieving primary and
secondary efﬁcacy endpoints. **p\0.01 for unadjusted
odds ratio of 1.2 (95% CI 1.07, 1.35) in favor of
vildagliptin. *p = 0.01 for unadjusted odds ratio of 1.2
(95% CI 1.05, 1.43) in favor of vildagliptin. Primary
endpoint: proportions of patients experiencing decreased
HbA1c of [0.3%, without hypoglycemia, weight gain,
peripheral edema, or gastrointestinal side-effects. Second-
ary endpoint: proportion of patients reaching HbA1c\7%
with no hypoglycemic events and weight gain. OAD oral
antidiabetes drugs, HbA1c glycosylated hemoglobin
Fig. 3 Mean change in glycosylated hemoglobin (HbA1c)
from baseline to study endpoint
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baseline was 1.21 kg in the vildagliptin cohort
vs. 0.37 kg in the comparator OAD cohort with
a between-treatment difference of -0.84 kg
(p\0.001).
DISCUSSION
The present study provides real-life data
regarding the effectiveness and tolerability of
vildagliptin combinations compared with other
OAD combinations in patients with T2DM in
Germany. The results demonstrate that
vildagliptin as an add-on to other OAD
monotherapy provides better glycemic control
than comparator OADs, without peripheral
edema, hypoglycemic events, discontinuation
due to a gastrointestinal event, or weight gain
C5%.
The responder rate of HbA1c \7.0% without
hypoglycemia and weight gain observed in the
present analyses is consistent with those from a
post hoc analysis of data from a 2-year,
randomized controlled study that compared
vildagliptin 50 mg bid with glimepiride as add-
on to metformin [13]. In that study, the
proportion of patients reaching the composite
endpoint was higher in the vildagliptin-treated
patients (29.8%) than glimepiride-treated
patients (19.4%) [13].
The HbA1c drop seen in the present post hoc
analysis (-0.7% with vildagliptin cohort vs.
-0.6% with comparator OAD) is comparable
with the HbA1c drop observed with vildagliptin
vs. other OADs (-0.9% vs. -0.6%) in a large
6-month observational study in Germany [14].
Current treatment guidelines recommend
that it is important to avoid weight gain and
hypoglycemia in addition to achieving
glycemic targets [3]. The findings from the
present post hoc analyses demonstrated that
treatment with vildagliptin resulted in more
patients achieving glycemic targets without
weight gain and increased risk of
hypoglycemia, which is in line with those
recommendations.
Overall, vildagliptin was well tolerated and
had a good safety profile. Additionally, no new
safety findings or those related to any recently
discussed events in a controlled, randomized
setting in high-risk cardiovascular (CV)
populations treated with DPP-4 inhibitors such
as increased hospitalization due to congestive
heart failure (CHF) [15, 16], were identified in
this cohort. Treatment with vildagliptin is not
usually associated with an increased risk of
hypoglycemia. In the present study there were
slightly more hypoglycemic events with other
OADs as compared with vildagliptin. It should
be noted that voluntary reporting of AEs might
have led to unnoticed or under-reported events,
which is also a limitation of the present study.
Furthermore, being an open-label, real-life,
observational study by design, physicians could
have selected any drug based on their clinical
judgment, resulting in an imbalance in
treatment arms, clearly favoring the DPP-4
inhibitor, vildagliptin (6,679 patients in the
vildagliptin cohort vs. 1,695 patients in the
comparator OAD cohort). Moreover, the
patients were recruited both in specialty
centers and centers of routine care, which
might have resulted in poor quality and
missing data, thus, impacting the overall
results. Such data should have ideally been
excluded from the effectiveness analyses.
CONCLUSION
The study results demonstrate that in real-life
clinical practice, vildagliptin is associated with a
numerically greater HbA1c drop and a higher
proportion of patients reaching target HbA1c
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without tolerability findings compared with
other OADs in patients with T2DM in Germany.
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